Go to Contents
ABOUT US
Company History
Contact Us
PIPELINE
Development Pipeline
BAL0891
SJ-600 Series
Pexa-Vec(JX-594)
JX-900 Series
TECHNOLOGY
GEEV ®
SOLVE ®
Scientific Publications
PARTNERSHIP
Global
Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
Sillajen Sitemap
ABOUT US
Company History
Contact Us
PIPELINE
Development Pipeline
BAL0891
SJ-600 Series
Pexa-Vec (JX-594)
JX-900 Series
TECHNOLOGY
GEEV ®
SOLVE ®
Scientific Publications
PARTNERSHIP
Global Partnership
IR/PR
Publications & News
Financials
IR Inquiries
SillaJen Biotherapeutics
About SillaJen Biotherapeutics
Contact Us
ENG
|
KOR
ENG
ENG
KOR
Targeting, Attacking, and Eradicating Cancers®
TOP
IR/PR
ABOUT US
TECHNOLOGY
PIPELINE
PARTNERSHIP
IR/PR
SillaJen Biotherapeutics
Notice & News
Publications & News
Financials
IR Inquiries
Notice & News
게시판
[AACR] Sillajen’s TNBC candidate BAL0891 study results accepted for three poster presentations
2025-01-16
Link address :
https://www.thebionews.net/news/articleView.html?idxno=12106
Targeting, Attacking, and Eradicating Cancers®
